Cancer combo trial pulled before it even started
NCT ID NCT04031872
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to test a combination of two drugs—LY3200882 and capecitabine—in people with advanced colorectal cancer that had stopped responding to chemotherapy. The goal was to see if the combination could re-sensitize tumors to treatment. However, the trial was withdrawn before enrolling any patients, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3200882 (a TGF-beta inhibitor) combined with capecitabine (a chemotherapy drug)
What this could lead to
If it had worked, this could have pointed toward a new treatment option for people with chemotherapy-resistant colorectal cancer.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination would have been safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.